Lipocine (NASDAQ: LPCN) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.48) by 12.5 percent. This is a 54.29 percent decrease over losses of $(0.35) per share from the same period last year. The company reported quarterly sales of $119.397 million which beat the analyst consensus estimate of $162.500 thousand by 73.38K percent. This is a 127.10K percent increase over sales of $93.864 thousand the same period last year.